Given that tumor-infiltrating lymphocytes (TILs) have been found to be more extensive in TNBC than in other breast cancer subtypes, randomized clinical trials have been conducted to investigate the strategy of combining immune checkpoint inhibitors (such as anti-PD-1 and anti-PD-L1) with traditional chemotherapy in NAC. This evidence concerns the gene CD274 and breast carcinoma.